| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Rangaramanujam M Kannan | |
| Qingguo Xu | |||
| Siva P Kambhampati | |||
| P2860 | cites work | Comparison of sutures and dendritic polymer adhesives for corneal laceration repair in an in vivo chicken model | Q83643741 |
| Extended drug delivery by contact lenses for glaucoma therapy | Q84431211 | ||
| Extended cyclosporine delivery by silicone-hydrogel contact lenses | Q84538585 | ||
| Photo cross-linkable Biodendrimers as ophthalmic adhesives for central lacerations and penetrating keratoplasties. | Q51017837 | ||
| Intravitreal pharmacokinetics of plain and liposome-entrapped fluconazole in rabbit eyes. | Q51369781 | ||
| Role of transporters in ocular drug delivery system. | Q51765779 | ||
| Polyamidoamine (PAMAM) dendrimers as biocompatible carriers of quinolone antimicrobials: an in vitro study. | Q54445800 | ||
| Pharmacokinetics of intravitreal ranibizumab (Lucentis). | Q55046220 | ||
| Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration | Q61865891 | ||
| A preliminary study of corneal penetration of 125I-labelled idoxuridine liposome | Q69605634 | ||
| Idoxuridine-liposome therapy for herpes simplex keratitis | Q71500292 | ||
| Temperature sensitive contact lenses for triggered ophthalmic drug delivery | Q83061664 | ||
| Exploiting dendrimer multivalency to combat emerging and re-emerging infectious diseases | Q26852693 | ||
| A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles | Q27349737 | ||
| Gene therapy in the cornea: 2005--present | Q30459643 | ||
| Ocular drug delivery | Q30475605 | ||
| Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model | Q30528069 | ||
| A photopolymerized sealant for corneal lacerations. | Q30730336 | ||
| Effect of particle size of polymeric nanospheres on intravitreal kinetics | Q30976557 | ||
| Applications of liposomes in ophthalmology | Q33212563 | ||
| Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina | Q33380235 | ||
| Ocular delivery of compacted DNA-nanoparticles does not elicit toxicity in the mouse retina | Q33510137 | ||
| Neovascular glaucoma at king khaled eye specialist hospital - etiologic considerations | Q33530312 | ||
| Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa | Q33752902 | ||
| Evaluation of magnetic micro- and nanoparticle toxicity to ocular tissues | Q33920796 | ||
| Inhibition of bacterial growth and intramniotic infection in a guinea pig model of chorioamnionitis using PAMAM dendrimers | Q34012976 | ||
| Nanomedicine(s) under the microscope | Q34040806 | ||
| Nanotechnology in drug delivery and tissue engineering: from discovery to applications | Q34112647 | ||
| RETRACTED: Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide | Q34283230 | ||
| Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration | Q34650239 | ||
| Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications | Q34701929 | ||
| Liposomal drug delivery systems: an update review. | Q34708849 | ||
| Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids | Q34856993 | ||
| Nanospheres delivering the EGFR TKI AG1478 promote optic nerve regeneration: the role of size for intraocular drug delivery | Q35105415 | ||
| Drug delivery to the retina: challenges and opportunities | Q35116140 | ||
| Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids | Q39923954 | ||
| Evaluation of toxicity of commercial ophthalmic fluoroquinolone antibiotics as assessed on immortalized corneal and conjunctival epithelial cells. | Q39947594 | ||
| Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. | Q41442716 | ||
| Surfactant-laden soft contact lenses for extended delivery of ophthalmic drugs | Q41622043 | ||
| Intravitreal Poly(L-lactide) Microparticles Sustain Retinal and Choroidal Delivery of TG-0054, a Hydrophilic Drug Intended for Neovascular Diseases | Q41819222 | ||
| Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections | Q42105578 | ||
| Subconjunctivally implantable hydrogels with degradable and thermoresponsive properties for sustained release of insulin to the retina. | Q42270577 | ||
| Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. | Q43059687 | ||
| Thiolated quaternary ammonium-chitosan conjugates for enhanced precorneal retention, transcorneal permeation and intraocular absorption of dexamethasone | Q43156035 | ||
| Intravenously administered gold nanoparticles pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity | Q43239219 | ||
| Photocrosslinkable polysaccharides for in situ hydrogel formation | Q43509858 | ||
| Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability | Q44435875 | ||
| Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. | Q44526900 | ||
| Dendritic macromers as in situ polymerizing biomaterials for securing cataract incisions. | Q45093893 | ||
| Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides. | Q45858295 | ||
| Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. | Q45885254 | ||
| Vitreous: a barrier to nonviral ocular gene therapy | Q45887213 | ||
| Zero-order therapeutic release from imprinted hydrogel contact lenses within in vitro physiological ocular tear flow | Q46928303 | ||
| Controlled release of high molecular weight hyaluronic Acid from molecularly imprinted hydrogel contact lenses | Q47199344 | ||
| Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration | Q47357515 | ||
| Size-selective and in vitro assessment of inner blood retina barrier permeability | Q47358649 | ||
| Extended release of high molecular weight hydroxypropyl methylcellulose from molecularly imprinted, extended wear silicone hydrogel contact lenses | Q47375527 | ||
| Vesicular systems in ocular drug delivery: an overview | Q35617707 | ||
| Role of mucins in the function of the corneal and conjunctival epithelia | Q35624244 | ||
| Highly compacted DNA nanoparticles with low MW PEG coatings: in vitro, ex vivo and in vivo evaluation. | Q35631652 | ||
| Nanoparticle-mediated gene transfer specific to retinal pigment epithelial cells | Q35876917 | ||
| Nanoparticle-mediated delivery of shRNA.VEGF-a plasmids regresses corneal neovascularization | Q36009031 | ||
| The use of mucoadhesive polymers in ocular drug delivery | Q36273784 | ||
| Topical and systemic drug delivery to the posterior segments | Q36313595 | ||
| Injectable PAMAM dendrimer-PEG hydrogels for the treatment of genital infections: formulation and in vitro and in vivo evaluation | Q36566183 | ||
| Ocular nanoparticle toxicity and transfection of the retina and retinal pigment epithelium | Q36758812 | ||
| Nanostructured materials for applications in drug delivery and tissue engineering | Q36807625 | ||
| Wanted and unwanted properties of surface PEGylated nucleic acid nanoparticles in ocular gene transfer | Q36851453 | ||
| Corneal gene therapy | Q36913747 | ||
| Dendrimers as drug carriers: applications in different routes of drug administration | Q36920235 | ||
| Designing hydrogel adhesives for corneal wound repair | Q36949099 | ||
| Transcorneal permeation of L- and D-aspartate ester prodrugs of acyclovir: delineation of passive diffusion versus transporter involvement | Q37147862 | ||
| An experimental platform for systemic drug delivery to the retina. | Q37384028 | ||
| Impact of nanotechnology on drug delivery. | Q37389440 | ||
| Interfacial interaction between transmembrane ocular mucins and adhesive polymers and dendrimers analyzed by surface plasmon resonance | Q37402647 | ||
| Polymeric nanoparticulate system: a potential approach for ocular drug delivery | Q37426784 | ||
| Inner blood-retinal barrier transporters: role of retinal drug delivery | Q37537014 | ||
| Gene therapy for diseases of the cornea - a review | Q37643785 | ||
| Flt23k nanoparticles offer additive benefit in graft survival and anti-angiogenic effects when combined with triamcinolone | Q37716548 | ||
| Molecularly imprinted therapeutic contact lenses | Q37735178 | ||
| Nanoparticles for retinal gene therapy | Q37746102 | ||
| Systemic delivery of therapeutics to neuronal tissues: a barrier modulation approach | Q37756991 | ||
| Ocular drug delivery - a look towards nanobioadhesives | Q37822756 | ||
| Strategies for therapy of retinal diseases using systemic drug delivery: relevance of transporters at the blood-retinal barrier | Q37950461 | ||
| Liposomes for intravitreal drug delivery: a state of the art. | Q37979950 | ||
| In situ gel systems as 'smart' carriers for sustained ocular drug delivery | Q37995297 | ||
| Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma | Q38018840 | ||
| The movement of self-assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection | Q38465570 | ||
| Blindness in Saudi Arabia | Q39307468 | ||
| Ocular sustained release nanoparticles containing stereoisomeric dipeptide prodrugs of acyclovir | Q39557119 | ||
| Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies | Q39606841 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported | Q15643954 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | gene therapy | Q213901 |
| targeted therapy | Q492646 | ||
| drug delivery | Q1392806 | ||
| nanotechnology | Q11468 | ||
| eye disease | Q3041498 | ||
| drug delivery system | Q64829245 | ||
| biomedical investigative technique | Q66648976 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 26-37 | |
| P577 | publication date | 2013-01-01 | |
| P1433 | published in | Middle East African Journal of Ophthalmology | Q6841320 |
| P1476 | title | Nanotechnology approaches for ocular drug delivery | |
| P478 | volume | 20 |
| Q90395446 | A novel dendrimer-based complex co-modified with cyclic RGD hexapeptide and penetratin for noninvasive targeting and penetration of the ocular posterior segment |
| Q89993054 | Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents |
| Q92752993 | Advances in Biodegradable Nano-Sized Polymer-Based Ocular Drug Delivery |
| Q42533421 | Conducting polymer nanoparticles decorated with collagen mimetic peptides for collagen targeting |
| Q41597703 | Corticosteroid-loaded biodegradable nanoparticles for prevention of corneal allograft rejection in rats |
| Q59060927 | Cyclosporine A Loaded PLGA Nanoparticles for Dry Eye Disease:In VitroCharacterization Studies |
| Q37225620 | Efficacy and safety of dendrimer nanoparticles with coexpression of tumor necrosis factor-α and herpes simplex virus thymidine kinase in gene radiotherapy of the human uveal melanoma OCM-1 cell line |
| Q26776374 | Facets of Nanotechnology as Seen in Food Processing, Packaging, and Preservation Industry |
| Q92626188 | Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration |
| Q47809046 | Folate Conjugated Hybrid Nanocarrier for Targeted Letrozole Delivery in Breast Cancer Treatment |
| Q88483868 | Formulation Development, Optimization, and In Vitro-In Vivo Characterization of Natamycin-Loaded PEGylated Nano-Lipid Carriers for Ocular Applications |
| Q47442388 | Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation. |
| Q38831205 | Nanocrystal for ocular drug delivery: hope or hype |
| Q35645705 | Nanoengineering of therapeutics for retinal vascular disease |
| Q37281194 | Nanomedicine in cerebral palsy |
| Q55491207 | Nanotechnology in retinal drug delivery. |
| Q43203868 | Ocular therapeutics of the future |
| Q49996892 | Ophthalmic Drug Delivery Systems for Antibiotherapy-A Review. |
| Q54195898 | PLGA nanoparticles for intravitreal peptide delivery: statistical optimization, characterization and toxicity evaluation. |
| Q94588015 | Retinal Photoreceptors Targeting SA-g-AA Coated Multilamellar Liposomes Carrier System for Cytotoxicity and Cellular Uptake Evaluation |
| Q48824231 | Subconjunctival injectable dendrimer-dexamethasone gel for the treatment of corneal inflammation. |
| Q38550131 | The role of nanotechnology in control of human diseases: perspectives in ocular surface diseases |
| Q37082827 | Therapeutic effect of apatinib-loaded nanoparticles on diabetes-induced retinal vascular leakage |
Search more.